logo
Plus   Neg
Share
Email

Novartis : EU Approves Mayzent For Treatment Of Adult Patients With SPMS

Novartis (NVS) said that the European Commission has approved Mayzent or siponimod for the treatment of adult patients with secondary progressive multiple sclerosis or SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

The company noted that Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population.

Multiple Sclerosis or MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.

Multiple Sclerosis, which affects about 2.3 million people worldwide, is often characterized into three forms: primary progressive MS (PPMS), relapsing-remitting MS (RRMS), and SPMS, which follows from an initial RRMS course and is characterized by physical and cognitive changes over time, in presence or absence of relapses, leading to a progressive accumulation of neurological disability.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Expedia Group Inc.(EXPE) plans to eliminate about 12 percent of its workforce or 3,000 jobs, following its disappointing 2019 business performance, according to reports citing an internal email from Expedia. The Job cuts will include around 500 at its Seattle headquarters. Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken.
Follow RTT
>